CARS2

Across TCGA pan-cancer cohorts, CARS2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CARS2 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CARS2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CARS2 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

HNSC, SKCM, and PRAD are the cancer types where CARS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.069	0.768	<.001	24	view →
SKCM	DFS	Median	All	0.096	0.742	<.001	24	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	OS	Median	III,IV	0.847	0.351	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CARS2–HNSC (OS)

Open the HNSC breakdown →